

Capacity of Monocytes from Patients with Chronic Myelomonocytic Leukemia to Differentiate into Macrophages and Multinucleated Giant Cells

Eriko Shoda^{1,2}, Eiji Kawano³, Katsunori Aoki², and Kiyoko S. Akagawa¹

Monocytes from patients with chronic myelomonocytic leukemia (CMML-Mo) strongly expressed CD14 and CD2, but not CD16. Macrophages (MΦ) generated from CMML-Mo expressed CD32, but not CD16. The expression levels of CD64 were significantly reduced from normal MΦ. While CMML-Mo-derived MΦ phagocytosed sensitized SRBC, these cells exhibited a similar defect as CMML-Mo in the ability to produce O₂⁻. CMML-Mo could generate dendritic cells (DC), but not multinucleated giant cells (MGC), suggesting that CMML-Mo are different from normal Mo in cell surface marker expression, O₂⁻ production, and the ability to differentiate into MΦ and MGC, but not DC.

Key words CMML, monocytes, macrophages

INTRODUCTION

Normal monocytes (Mo) can differentiate into macrophages (MΦ), osteoclast-like multinucleated giant cells (MGC), and dendritic cells (DC) in differing cytokine environments of macrophage colony-stimulating factor (M-CSF) alone, M-CSF and interleukin 4 (IL-4), and granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, respectively¹. Chronic myelomonocytic leukemia (CMML) is a myeloproliferative disorder exhibiting peripheral blood monocytosis. Although CMML-Mo are known to be able to differentiate into DC², there is no report examining if CMML-Mo can differentiate into MΦ or MGC. In this study, we investigate the ability of CMML-Mo to differentiate into MΦ and MGC following treatment with M-CSF and M-CSF+IL-4, respectively.

MATERIALS AND METHODS

Patients : CMML samples were obtained from four patients, whose clinical characteristics are detailed in Table 1. All samples were acquired after obtaining informed consent

Received : Jul 1, 2005

Revised : Aug 15, 2005

Accepted : Aug 16, 2005

¹Department of Immunology, National Institute of Infectious Diseases, Tokyo Japan,

²Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Japan

³Nippon Kayaku Company, Tokyo, Japan

Address correspondence and reprint request to Kiyoko S. Akagawa, Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjyuku-ku, Tokyo 162-8640, Japan

with the approval of the local ethics committee.

Preparation and culture of Mo : Mo were isolated from PBMCs obtained from CMML patients using a magnetic cell separation system (MACS ; Miltenyi Biotec, Bergisch Gladbach, Germany) with anti-CD14 mAb-coated microbeads as described³. CD14⁺ Mo were cultured for seven days at a density of $5 \times 10^5/2$ ml in RPMI1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) in the 6-well plates (Falcon ; Becton, Dickinson and Company, Franklin Lakes, NJ) at 37°C in an atmosphere of 5% CO₂ in air. Cultures were treated with M-CSF, GM-CSF+IL-4 or M-CSF+IL-4 at the following concentrations : 500 U/ml GM-CSF (Schering-Plough Japan, Osaka, Japan), 1×10^4 U/ml M-CSF (Morinaga Milk Industry Co., Ltd., Tokyo, Japan), and 100 U/ml IL-4 (GENZYME TECHNE, Minneapolis, MN).

Phenotypic analysis : Expression of cell surface markers was assessed using fluorescein (FITC)- and phycoerythrin (PE)-conjugated mouse mAbs specific for CD2, CD13, CD14, CD16, CD33, HLA-DR (BD, San Jose, CA), CD32, CD64 (BD Pharmingen, San Diego, CA), and CD1a (Beckman Coulter, Inc., Florida, MA), as well as isotype control mouse MoAbs (BD). To block nonspecific Fc-receptor-mediated binding of mAbs, cells were pre-incubated for 30 min at 0°C in normal goat serum (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada) before staining. Stained cells were analyzed using a FACS Calibur cytometer (BD) equipped with Cell Quest software (BD).

Phagocytosis of MΦ : MΦ derived from CMML-Mo in RPMI1640/10% FCS were incubated at 37°C with 0.2% latex particles (average diameter 1 μm, Dow Chemical Co., Indianapolis, IN, USA) for 4 hrs or with 0.4% sensitized sheep red blood cells (EA) for 1 hr, then washed three times in PBS

without Ca⁺⁺ or Mg⁺⁺.

Superoxide generation assay : To measure the amount of superoxide anion (O₂⁻) generated by cells stimulated with phorbol myristate acetate (PMA, 100 ng/ml), we used lucigenin-dependent SOD-inhibitable chemiluminescence⁴. The chemiluminescence response, measured every 10 min using a Berthold LB96P luminometer, was expressed as relative light units (RLU).

RESULTS AND DISCUSSION

Almost all the Mo obtained from four CMML patients expressed CD14, as well as HLA-DR, CD13, and CD33, as demonstrated by previous studies². The majority of the Mo derived from the four CMML patients, as well as normal-Mo, expressed CD32 and CD64 (Table 1). Consistent previous studies^{5,6}, approximately 22% (10-30%) and 31% (16-39%) of normal-Mo expressed CD16 and CD2, respectively. In contrast, CMML-Mo did not express significant levels of CD16 (0-3%), while increased cell numbers strongly expressed CD2 (59-99%) (Table 1, Fig. 1). The absence of CD16 expression by CMML-Mo correlates well with previous reports². Lack of CD16 expression and strong expression of CD2 by CMML-Mo suggest that CMML-CD14⁺Mo are less mature than normal-CD14⁺Mo.

Next, we examined the ability of CMML-Mo to differentiate into MΦ following M-CSF treatment. Culture of CMML-Mo in M-CSF induced the morphologic changes characteristic of Mo to MΦ differentiation, including an increase in size and adherence. The resulting morphology of CMML-Mo-derived MΦ (CMML-MΦ) resembled that of normal Mo-derived MΦ (normal-MΦ) (Fig. 2). CMML-MΦ exhibited normal phagocytosis of latex particles and the Fc-receptor-mediated internalization of EA (Table 1). As seen for normal MΦ, the majority of CMML-MΦ expressed CD32 ; surface expression of CD64 by CMML-MΦ, however, was lower than that seen by normal MΦ (Table 1, Fig. 3). CMML-MΦ did not express significant levels of CD16, which is expressed strongly by normal-MΦ^{7,8} (Table 1, Fig. 3). Previous studies have shown that the expression of CD16 by Mo and MΦ is enhanced by IL-10⁷ ; IL-10 is produced by Mo cultured in M-CSF⁹. Thus, the possibility exists that CMML-Mo are defective in IL-10 production following M-CSF stimulation. We do not currently understand, however, the mechanisms underlying the lack of CD16 expression by CMML-Mo and CMML-MΦ.

The production of reactive oxygen intermediates, such as O₂⁻, by Mo/MΦ plays a fundamental role in innate immune responses. These substances possess the ability to kill microbial pathogens within phagolysosomes. We therefore ex-

Table 1. Patient's characteristics at the time of obtaining of blood samples and immunophenotypic characteristics of normal and CMML Mo, and normal and CMML Mo-derived MΦ

Patient	Normal	No. 1	No. 2	No. 3	No. 4
Age/ Sex		63/ M	77/ F	66/ M	70/ M
Karyotype		46, XY	46, XX	46, XY	46, XY del(1)(p34), der(5; 17)(p10; q10), +8
Counts of Mo (× 10 ⁹ /l)		4.4	9.3	2.8	9.6
CD14 ⁺ CD16 ⁺ Mo (%)	22 (10~30)	0	3	1	1
CD14 ⁺ CD2 ⁺ Mo (%)	31 (16~39) (n = 5)	59	100	94	86
MΦCD14 (%)	96	93	82	81	99
CD16 (%)	85	8	16	8	1
CD32 (%)	100	80	86	87	95
CD64 (%)	87 (n = 5)	14	51	54	33
O ₂ ⁻ (RLU)Mo	558 (273~730)	14	117	239	174
MΦ	76 (33~99) (n = 3)	9	9	8	31

Percentage shows positive cells. O₂⁻ was showed RLU in peak value.




Fig. 1 Dot plot analysis of the expression of CD14, CD16, and CD2 by normal-Mo and CMML-Mo. The data shown, obtained using CMML-Mo derived from patient No. 3, are representative of CMML-Mo from the other three patients.

amined the O_2^- production by CMML-Mo and CMML-M Φ . In contrast to normal-Mo and normal-M Φ , neither CMML-Mo nor CMML-M Φ produced significant levels of O_2^- following PMA stimulation (Fig. 4). O_2^- is produced by the activation of NADPH oxidase, an enzyme consisting of six subunits; the integral membrane proteins p22^{phox} and gp91^{phox}, which form a heterodimeric flavocytochrome, bind four cytosolic proteins, the small GTPase Rac, p40^{phox}, p47^{phox}, and p67^{phox}¹⁰. Preliminary western blot analysis demonstrated that the protein levels of p47 and p67 in CMML-Mo were similar to those seen in normal-Mo (data not shown), suggesting either impairment of the remaining components of NADPH oxidase or aberrant activation of the oxidase signaling pathway in CMML-Mo/M Φ .

CMML-Mo cultured in GM-CSF and IL-4 differentiated into CD1a⁺ DC, as reported² (Fig. 2). Culture of CMML-Mo in M-CSF and IL-4, however, did not generate MGC (Fig. 2). These results suggest that the signaling pathway induced by the combination of M-CSF+IL-4, but not that activated by GM-CSF+IL-4, is impaired in CMML-Mo. The precise mechanisms governing the inability of CMML-Mo to generate MGC following M-CSF+IL-4 treatment remains unclear.




Fig. 2 Morphology of the cells generated from normal Mo and CMML-Mo following culture in M-CSF alone (upper), GM-CSF+IL-4 (middle), and M-CSF+IL-4 (lower). CMML-Mo shown were taken from patient No. 2; the CMML-Mo from the remaining three patients demonstrated similar results (data not shown). Phase-contrast micrographs are shown at an original magnification of $\times 200$.

In conclusion, CMML-Mo can differentiate into M Φ following M-CSF treatment; the M Φ generated, however, are distinct from normal Mo-derived M Φ in their expression of CD16 and capacity for O_2^- production. Although CMML-Mo are defective in their ability to differentiate into MGC following M-CSF+IL-4 treatment, these cells can differentiate into DC when given GM-CSF+IL-4. It will be interesting to use CMML-Mo to elucidate the signaling pathways involved in the differentiation of Mo into M Φ and/or MGC that require M-CSF and/or M-CSF+IL-4.

REFERENCE

- 1 Akagawa KS, Takasuka N, Nozaki Y, Komuro I, Azuma M, Ueda M, Naito M, Takahashi K: Generation of CD1⁺ReIB⁺ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. *Blood* 88: 4029-4039, 1996
- 2 Vuckovic S, Fearnley DB, Gunningham S, Spearing RL, Patton WN, Hart DN: Dendritic cells in chronic myelomonocytic leukaemia. *Brit J Haematol* 105: 974-985, 1999
- 3 Komuro I, Keicho N, Iwamoto A, Akagawa KS: Human alveolar macrophages and granulocyte-macrophage colony-stimulating factor-induced monocyte-derived macrophages are resistant to H_2O_2 via their high basal and inducible levels of catalase activity.




Fig. 3 Phenotypic analysis of MΦ generated from normal-Mo (left side) and CMML-Mo (right side) by M-CSF stimulation. The dotted line represents the isotype control. The data shown, detailing the results of CMML-Mo-derived MΦ from patient No. 1, were representative of all CMML patients.

J Biol Chem 276 : 24360-24364, 2001

- 4 Yu D, Imajoh-Ohmi S, Akagawa K, Kanegasaki S : Suppression of superoxide-generating ability during differentiation of monocytes to dendritic cells. J Biochem 119 : 23-28, 1996
- 5 Passlick B, Flieger D, Ziegler-Heitbrock HW : Identification and




Fig. 4 PMA-stimulated O_2^- production by normal-Mo and CMML-Mo (a) and normal-MΦ and CMML-MΦ (b). Data for the normal-Mo and normal-MΦ are representative of cells from three normal subjects.

characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74 : 2527-2534, 1989

- 6 Crawford K, Gabuzda D, Pantazopoulos V, Xu J, Clement C, Reinherz E, Alper CA : Circulating $CD2^+$ monocytes are dendritic cells. J Immunol 163 : 5920-5928, 1999
- 7 Hashimoto SI, Komuro I, Yamada M, Akagawa KS : IL-10 inhibits granulocyte-macrophage colony-stimulating factor-dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J Immunol 167 : 3619-3625, 2001
- 8 Young DA, Lowe LD, Clark SC : Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 145 : 607-615, 1990
- 9 Mochida-Nishimura K, Akagawa KS, Rich EA : Interleukin-10 contributes development of macrophage suppressor activities by macrophage colony-stimulating factor, but not by granulocyte-macrophage colony-stimulating factor. Cell Immunol 214 : 81-88, 2001
- 10 Groemping Y, Lapouge K, Smerdon SJ, Rittinger K : Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 113 : 343-355, 2003